Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept in SOJRA
NCT00078806Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jun 2001
- Primary completion
- May 2004
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 3, randomised, double-blind trial of etanercept in systemic juvenile idiopathic arthritis (sJIA) (4 arms), sponsored by Amgen. Primary endpoint: Number of Participants in Part 2 With Disease Flare at 3 months. Started Jun 2001; status: terminated.
02
Drugs
etanercept
03
Conditions
systemic juvenile idiopathic arthritis (sJIA)
Beyond the preview
Go deeper on NCT00078806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078806.